Skip to main content
. 2016 Oct 12;3(6):e289. doi: 10.1212/NXI.0000000000000289

Figure 5. Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment.

Figure 5

(A) Gating strategy for ILCs. ILCs were defined as lineage (CD3, CD14, CD19, CD20)–negative peripheral blood mononuclear cells (PBMCs) devoid for dendritic cell (DC) markers CD123 and CD11c. CD56brightCD16dim/− natural killer (NK) cells were gated from CD56+NKp46+ ILC, whereas CD117+CRTH2− lymphoid tissue inducer cells (LTis) were gated from CD56−NKp46− ILCs. (B) Graphs display proportions of ILCs within PBMCs or ILC subsets within ILCs (upper row) and total cell numbers (lower row) of ILC subsets derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up (open triangles). (C) Release of cytolytic granules by NK cells at baseline and 6 months after alemtuzumab therapy (n = 7) in response to K562 (left), 721.221 (middle), or antigen-activated allogenic CD4+ T cells. p Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *p < 0.05, **p < 0.01, ***p < 0.001.